On October 2, 2025 Biosceptre International Limited reported the successful completion of its 2025 fundraise, securing £8.1 million through the issue of 40,500,000 new shares (Press release, Biosceptre, OCT 2, 2025, View Source;utm_medium=rss&utm_campaign=biosceptre-secures-8-1-million-to-accelerate-innovative-cancer-therapies [SID1234656397]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This achievement underscores the strong confidence of investors in Biosceptre’s pioneering approach to developing novel treatments for hard-to-treat cancers.

Biosceptre CEO Gavin Currie commented:

"This fundraise marks an important milestone for Biosceptre as we accelerate the development of our therapeutic pipeline. With the continued support of our investors, we are advancing towards our vision of bringing transformative treatments to patients worldwide. Our team is deeply committed to tackling some of the most pressing challenges in oncology and to building a future where patients have access to more effective and targeted therapies."

With this new capital in place, Biosceptre will continue to progress its therapeutic pipeline and deliver on key milestones in the months ahead.

The newly issued shares are scheduled to be dispatched by 8th October 2025.